FDA OKs BrainsWay non-invasive device to treat OCD in adults

By JERUSALEM POST STAFF
August 19, 2018 22:16
1 minute read.
Brain scan

Brain scan (illustrative). (photo credit: ING IMAGE/ASAP)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Israel’s BrainsWay Ltd., which creates advanced non-invasive treatment for brain disorders, announced on Sunday that it has received de novo clearance from the US Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

This clearance represents the first ever non-invasive medical device clearance for the treatment of OCD. BrainsWay intends to start using the approved system as an upgrade for its current systems and as part of new installations. Clinics that have or will have a Deep TMS systems can now treat patients with major depressive disorders (MDD) and OCD.

Be the first to know - Join our Facebook page.


“With the clearance of our BrainsWay OCD device, we are now able to provide an effective and safe treatment option for US patients who are suffering from OCD,” said Yaacov Michlin, the president and chief executive officer of BrainsWay. “With more than two million US adults suffering from OCD, this clearance provides us with a significant market opportunity.

“Importantly, this clearance further establishes Deep TMS as a platform technology that will provide treatments for additional psychiatric indications, subject to successful completion of our currently ongoing multi center studies and regulatory approvals.”

BrainsWay’s Deep TMS technology differs from that of other focal TMS devices as it has broad applicability and can directly stimulate areas of the brain at a greater depth and breadth than any other TMS device on the market safely and efficiently.

While other focal TMS devices are limited to treating MDD, BrainsWay can now directly target previously unreachable areas of the brain with its proprietary H7-coil, allowing it to effectively treat OCD as well.

“The clearance of BrainsWay’s OCD device marks a historic milestone in the treatment of this neurological disorder,” said Dr. Joseph Zohar, a professor of psychiatry at the Sackler Faculty of Medicine at Tel Aviv University. “This is a new groundbreaking treatment option for patients looking for a meaningful and potentially life-changing solution for OCD.”


JPOST VIDEOS THAT MIGHT INTEREST YOU:

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Prime Minister Benjamin Netanyahu (C) receives applause at a weekly faction meeting
November 19, 2018
Netanyahu, victorious, says coalition to stay intact for another year

By LAHAV HARKOV